News from the debiopharm group A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( Australia:NWS,Australia:NWSLV,NASDAQ-NMS:CME,NASDAQ-NMS:NWSA,OTC-PINK:NZCPF,NYSE:MHP,NASDAQ-NMS:NWS)

Feb 09, 2010, 03:30 ET

Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that...

Feb 04, 2010, 01:30 ET

Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer

Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based...

Oct 13, 2009, 01:30 ET

Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that...

Oct 05, 2009, 02:30 ET

The Japanese Cancer Association and Debiopharm Group Present the JCA-Mauvernay Award to Dr Ushijima for his Oncology Research

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that...

Sep 07, 2009, 02:30 ET

Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent

Ipsen (Euronext:IPN), an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global...

Sep 03, 2009, 11:00 ET

The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection

Debiopharm Group, SA (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs...

Aug 04, 2009, 04:30 ET

Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs...

Jul 30, 2009, 04:58 ET

Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs...

Jul 21, 2009, 05:18 ET

Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that...

Jun 23, 2009, 05:48 ET

Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that...

May 11, 2009, 06:51 ET

Debiopharm and Mepha Sign Distribution Agreement for Pamorelin(R) LA

- 1- 3- and 6-Month Formulations - A new Treatment for Prostate Cancer Patients in Switzerland Debiopharm Group (Debiopharm), a global...

Apr 30, 2009, 05:05 ET

Clinical Update - Debio 025 in Hepatitis C

Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions, particularly in the...

Apr 28, 2009, 04:47 ET

Clinical Update - Debio 025 in Hepatitis C

Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions, particularly in the...

Nov 20, 2008, 04:00 ET

Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway

Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and...

Nov 17, 2008, 04:00 ET

Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions

Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly...

Nov 13, 2008, 16:00 ET

Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer

Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and...

Nov 04, 2008, 11:19 ET

Sanvar(R) (Debio 8609) for Esophageal Variceal Bleeding

Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly...

Sep 02, 2008, 01:00 ET

Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate for Cancer Treatment

LAUSANNE, Switzerland, September 2 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist...

May 15, 2008, 01:00 ET

Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations

LAUSANNE, Switzerland, May 15 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist...

Apr 14, 2008, 01:00 ET

Debiopharm and Airmid Sign Option and License Agreement for the Development of Debio 0824, an ShK Peptide for Autoimmune Disorders

LAUSANNE, Switzerland, April 14 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist in...